10 Jul 2026

CRC Research Update — July 10, 2026

Creator: The CRC Digest
Published: 2026-07-10T12:15:36Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

Pembrolizumab Remains Most Mature First-Line Standard for MSI-H/dMMR Metastatic CRC
A new review of landmark trials confirms pembrolizumab as the most mature first-line single-agent standard for MSI-H/dMMR metastatic colorectal cancer, with superior progression-free and overall survival versus chemotherapy and a well-characterized long-term safety profile. (J Gastrointest Cancer)
Meta-Analysis Quantifies Anti-HER2 Therapy Benefit in HER2-Positive Metastatic CRC
A systematic review and meta-analysis of phase II/III trials examined anti-HER2 treatments in HER2-overexpressed metastatic colorectal cancer, pooling objective response rate, disease control rate, progression-free survival, and overall survival data. (Oncologist)
CRC Mortality Declines Across 48 Countries Linked to Screening and Early Detection
Analysis of mortality data from 1950 to 2019 across 48 countries shows substantial progress in reducing colorectal cancer deaths, with avoided deaths estimated as the difference between expected and observed mortality following peak years. (JCO Glob Oncol)
Meta-Analysis Compares TAS-102 and Regorafenib Sequencing in Later-Line mCRC
A systematic review and meta-analysis compared efficacy and safety of TAS-102 followed by regorafenib versus the reverse sequence in patients with metastatic colorectal cancer who had previously failed chemotherapy. (Chin Clin Oncol)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

Sotorasib Plus Panitumumab Produces Response in Rare NRAS G12C-Mutated MSI-H Rectal Cancer
A case report describes an objective tumor response to the KRAS G12C inhibitor sotorasib combined with EGFR blockade in a patient with advanced NRAS G12C-mutated, mismatch repair-deficient rectal adenocarcinoma refractory to immunotherapy. (Cureus)
Stage III/IV MSI-H CRC Shows Reduced T-Cell Infiltration and Elevated IDO1
Analysis of 217 patients with dMMR/MSI-H colorectal cancer found that stage III/IV tumors had reduced immune infiltration and upregulated epithelial IDO1 expression compared to stage I/II, suggesting immune evasion mechanisms in locally advanced disease. (Oncoimmunology)

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

New Review Outlines Tailored Screening for Lynch Syndrome and Polyposis Syndromes
A comprehensive review summarizes current evidence on CRC risk and screening strategies for hereditary cancer syndromes and family history, emphasizing that these higher-risk groups require different age of initiation, surveillance intervals, and modality compared to population-based approaches. (Int J Cancer)
National Study Examines Follow-Up Colonoscopy Rates After Positive Stool Tests by Race and Ethnicity
A retrospective cohort study linking national data from 2016 to 2023 evaluated follow-up colonoscopy rates, time to colonoscopy, and compliance predictors after positive FIT, FOBT, or mt-sDNA tests, noting that delays are associated with higher CRC incidence and mortality. (J Natl Compr Canc Netw)

Today's research highlights progress in biomarker-driven treatment, screening equity, and understanding immune evasion in advanced disease.

Subscribe to The CRC Digest